{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:00:25Z","timestamp":1769882425975,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A5A2023127"],"award-info":[{"award-number":["NRF-2018R1A5A2023127"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.msard.2023.105145","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:52:19Z","timestamp":1700545939000},"page":"105145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Latent tuberculosis infection in Korean patients with multiple sclerosis and neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"81","author":[{"given":"Ki Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2023.105145_bib0001","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.msard.2023.105145_bib0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet. Respir. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.105145_bib0003","article-title":"Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting","volume":"5","author":"Baldassari","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00096-21","article-title":"Retrospective performance analyses of over two million U.S. QuantiFERON blood sample results","volume":"9","author":"Bi","year":"2021","journal-title":"Microbiol. Spectr."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7224\/1537-2073.2019-015","article-title":"Prevalence of latent tuberculosis in the multiple sclerosis clinic and effect of multiple sclerosis treatment on tuberculosis testing","volume":"23","author":"Bouley","year":"2021","journal-title":"Int. J. MS Care"},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00430-016-0482-x","article-title":"Effect of teriflunomide on QuantiFERON-TB Gold results","volume":"206","author":"Bua","year":"2017","journal-title":"Med. Microbiol. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2023.105145_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"9856","key":"10.1016\/j.msard.2023.105145_bib0008","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2023.105145_bib0009","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2023.105145_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"9843","key":"10.1016\/j.msard.2023.105145_bib0011","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(12)61401-9","article-title":"Breathlessness, night sweats, and weight loss on natalizumab","volume":"380","author":"Dahdaleh","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105145_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103184","article-title":"Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: a systematic review","volume":"55","author":"Dantas","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105145_bib0013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/IDR.S8994","article-title":"The use of anti-tuberculosis therapy for latent TB infection","volume":"3","author":"Denholm","year":"2010","journal-title":"Infect. Drug Resist."},{"issue":"8","key":"10.1016\/j.msard.2023.105145_bib0014","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.11-0992","article-title":"Challenges of interferon-\u03b3 release assay conversions in serial testing of health-care workers in a TB control program","volume":"142","author":"Fong","year":"2012","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.msard.2023.105145_bib0016","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/14737175.2014.962517","article-title":"How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert. Rev. Neurother."},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00296-017-3852-9","article-title":"IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"12","key":"10.1016\/j.msard.2023.105145_bib0018","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/acn3.491","article-title":"Infectious risk stratification in multiple sclerosis patients receiving immunotherapy","volume":"4","author":"Graf","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2023.105145_bib0019","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(18)30625-X","article-title":"Global, regional, and national burden of tuberculosis, 1990-2016: results from the global burden of diseases, injuries, and risk factors 2016 study","volume":"18","author":"Hmwe Hmwe Kyu","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3904\/kjim.2020.029","article-title":"Latent tuberculosis infection: recent progress and challenges in South Korea","volume":"35","author":"Jeon","year":"2020","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3346\/jkms.2015.30.2.167","article-title":"Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels","volume":"30","author":"Jeong","year":"2015","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.msard.2023.105145_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187313","article-title":"A borderline range for Quantiferon Gold In-Tube results","volume":"12","author":"Jonsson","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.msard.2023.105145_bib0024","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00296-014-3033-z","article-title":"Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases","volume":"34","author":"Jung","year":"2014","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.msard.2023.105145_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. America"},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1164\/rccm.201203-0430OC","article-title":"Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice","volume":"187","author":"Metcalfe","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.msard.2023.105145_bib0028","doi-asserted-by":"crossref","first-page":"30781","DOI":"10.1038\/srep30781","article-title":"Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: a Markov model","volume":"6","author":"Moses","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0029","article-title":"Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis","volume":"4","author":"Navas","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"5","key":"10.1016\/j.msard.2023.105145_bib0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1164\/rccm.201704-0817OC","article-title":"Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection","volume":"196","author":"Nemes","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.msard.2023.105145_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221077817","article-title":"In-hospital blood collection increases the rate of indeterminate results in interferon-gamma release assays","volume":"16","author":"Osakabe","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.msard.2023.105145_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030507","article-title":"Impact of immunosuppressive therapy on the performance of latent tuberculosis screening tests in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Park","year":"2022","journal-title":"J. Pers. Med."},{"issue":"12","key":"10.1016\/j.msard.2023.105145_bib0033","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.arbr.2015.05.009","article-title":"Immunomodulating effects of glatiramer acetate and its potential role in pulmonary tuberculosis reactivation","volume":"51","author":"Sanchez-Salcedo","year":"2015","journal-title":"Arch. Bronconeumol. (English Edition)"},{"issue":"8","key":"10.1016\/j.msard.2023.105145_bib0034","doi-asserted-by":"crossref","first-page":"ofy184","DOI":"10.1093\/ofid\/ofy184","article-title":"Risk factors for indeterminate outcome on interferon gamma release assay in non-US-born persons screened for latent tuberculosis infection","volume":"5","author":"Sharninghausen","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"10.1016\/j.msard.2023.105145_bib0035","article-title":"Active pulmonary tuberculosis triggered by interferon beta-1b therapy of multiple sclerosis: four case reports and a literature review","volume":"56","author":"Sirbu","year":"2020","journal-title":"Medicina (Kaunas)."},{"issue":"1","key":"10.1016\/j.msard.2023.105145_bib0036","first-page":"1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports: morbidity and mortality weekly report","volume":"69","author":"Sterling","year":"2020","journal-title":"Recommend. Rep."},{"key":"10.1016\/j.msard.2023.105145_bib0037","article-title":"Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers","author":"Thanassi","year":"2012","journal-title":"Pulmon. Med. 2012"},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0038","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105145_bib0039","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis \u2013 Tests for Tuberculosis Infection","year":"2022"},{"issue":"2","key":"10.1016\/j.msard.2023.105145_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:02:56Z","timestamp":1719968576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823006466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"alternative-id":["S2211034823006466"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105145","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latent tuberculosis infection in Korean patients with multiple sclerosis and neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105145"}}